|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Maia Biotechnology, Inc. (MAIA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
10,950,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Co.'s primary product candidate, 6-thio-dG or 6-thio-2'-deoxyguanosine (THIO), is a telomere-targeting agent in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). THIO is being developed as a second- or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. Co.'s pipeline includes THIO-102, which is targeting colorectal cancer and THIO-103, which is targeting basket study.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
619,888 |
619,888 |
619,888 |
1,201,412 |
| Total Buy Value |
$869,025 |
$869,025 |
$869,025 |
$3,108,759 |
| Total People Bought |
5 |
5 |
5 |
10 |
| Total Buy Transactions |
7 |
7 |
7 |
97 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Stan |
Director |
• • – |
2022-12-30 |
4 |
AB |
$3.50 |
$1,750 |
I/I |
500 |
513,328 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-29 |
4 |
AB |
$3.49 |
$5,134 |
I/I |
1,471 |
512,828 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-28 |
4 |
AB |
$3.41 |
$4,317 |
I/I |
1,266 |
511,357 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-27 |
4 |
AB |
$3.38 |
$2,042 |
I/I |
604 |
510,091 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-23 |
4 |
AB |
$3.45 |
$3,384 |
I/I |
981 |
509,487 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-22 |
4 |
AB |
$3.34 |
$2,442 |
I/I |
731 |
508,506 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-21 |
4 |
AB |
$3.43 |
$1,369 |
I/I |
399 |
507,775 |
|
- |
|
| Smith Stan |
Director |
• • – |
2022-12-20 |
4 |
AB |
$3.53 |
$14,289 |
I/I |
4,048 |
507,376 |
|
- |
|
| Gryaznov Sergei |
Chief Scientific Officer |
• • – |
2022-12-07 |
4 |
OE |
$1.83 |
$18,300 |
D/D |
10,000 |
44,511 |
|
- |
|
| Guerrero Ramiro |
Director |
• • – |
2022-09-13 |
4 |
B |
$3.85 |
$33,875 |
D/D |
8,799 |
297,464 |
2.39 |
- |
|
| Guerrero Ramiro |
Director |
• • – |
2022-08-30 |
4 |
B |
$3.97 |
$1,125 |
D/D |
283 |
288,665 |
2.31 |
- |
|
| Gryaznov Sergei |
Chief Scientific Officer |
• – – |
2022-08-24 |
4 |
OE |
$1.80 |
$18,000 |
D/D |
10,000 |
34,511 |
|
- |
|
| Vitoc Vlad |
Chief Executive Officer |
• • • |
2022-08-01 |
4/A |
B |
$5.00 |
$50,000 |
I/I |
10,000 |
210,000 |
2.64 |
- |
|
| Mcguire Joseph F |
Chief Financial Officer |
• – – |
2022-08-01 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Obrocea Mihail |
Chief Medical Officer |
• – – |
2022-08-01 |
4 |
B |
$5.00 |
$5,000 |
D/D |
1,000 |
27,100 |
2.74 |
- |
|
| Chaouki Steven M |
Director |
– • – |
2022-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
54,250 |
|
- |
|
| Chaouki Steven M |
Director |
– • – |
2022-08-01 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
46,250 |
2.39 |
- |
|
| Guerrero Ramiro |
Director |
– • – |
2022-08-01 |
4 |
B |
$5.00 |
$100,000 |
D/D |
20,000 |
288,382 |
2.39 |
- |
|
| Smith Stan |
Director |
– • – |
2022-08-01 |
4 |
A |
$0.00 |
$0 |
I/I |
7,200 |
503,328 |
|
- |
|
| Smith Stan |
Director |
– • – |
2022-08-01 |
4 |
B |
$5.00 |
$1,000,000 |
I/I |
200,000 |
496,128 |
2.1 |
- |
|
| Gryaznov Sergei |
Chief Scientific Officer |
• – – |
2022-08-01 |
4 |
B |
$5.00 |
$15,000 |
D/D |
3,000 |
24,511 |
2.74 |
- |
|
| Louie Ngar Yee |
Director |
– • – |
2022-08-01 |
4 |
B |
$5.00 |
$100,000 |
D/D |
20,000 |
928,584 |
2.39 |
- |
|
| Vlad Laurentiu |
Director |
– • – |
2022-08-01 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
376,933 |
2.39 |
- |
|
| Vitoc Vlad |
Chief Executive Officer |
• • • |
2022-08-01 |
4 |
B |
$5.00 |
$30,000 |
D/D |
6,000 |
789,121 |
3.23 |
- |
|
| Luput Cristian |
Director |
– • – |
2022-08-01 |
4 |
B |
$5.00 |
$2,500 |
D/D |
500 |
278,068 |
2.31 |
- |
|
111 Records found
|
|
Page 4 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
